CA3154027A1 - Use of cyclic amide derivatives to treat sigma receptor-mediated disorders - Google Patents
Use of cyclic amide derivatives to treat sigma receptor-mediated disordersInfo
- Publication number
- CA3154027A1 CA3154027A1 CA3154027A CA3154027A CA3154027A1 CA 3154027 A1 CA3154027 A1 CA 3154027A1 CA 3154027 A CA3154027 A CA 3154027A CA 3154027 A CA3154027 A CA 3154027A CA 3154027 A1 CA3154027 A1 CA 3154027A1
- Authority
- CA
- Canada
- Prior art keywords
- symptom
- compound
- formula
- treatment
- sigma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Agronomy & Crop Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| US61/366,080 | 2010-07-20 | ||
| CA2805904A CA2805904C (en) | 2010-07-20 | 2011-07-20 | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2805904A Division CA2805904C (en) | 2010-07-20 | 2011-07-20 | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3154027A1 true CA3154027A1 (en) | 2012-01-26 |
Family
ID=45497167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154027A Pending CA3154027A1 (en) | 2010-07-20 | 2011-07-20 | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
| CA2805904A Active CA2805904C (en) | 2010-07-20 | 2011-07-20 | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2805904A Active CA2805904C (en) | 2010-07-20 | 2011-07-20 | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20130274290A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4070794A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2013531073A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101867634B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107007603A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013001302A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3154027A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2595485T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2914120T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE058736T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2595485T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2595485T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2746871C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI520949B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012012543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| US9458130B2 (en) | 2014-12-02 | 2016-10-04 | Minerva Neurosciences, Inc. | Compositions and methods for treating schizophrenia |
| CN113694065A (zh) * | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| AU2018290287B2 (en) * | 2017-06-21 | 2024-06-13 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| WO2020041504A1 (en) * | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| JP2023526515A (ja) | 2020-05-20 | 2023-06-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | リソソーム蓄積症をヒスタチンペプチドで処置するための方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR927002347A (ko) * | 1989-10-27 | 1992-09-03 | 레이몬드 지. 아너 | (n-프탈이미도알킬) 피페리딘 |
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| ATE201677T1 (de) * | 1992-04-23 | 2001-06-15 | Merrell Pharma Inc | 4-imidomethyl-1-(2'-phenyl-2-oxoethyl)-piperidi e als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung |
| DE60129210T2 (de) * | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | Zyklische amid-derivate |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en not_active Ceased
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active Active
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en not_active Abandoned
-
2025
- 2025-01-15 US US19/021,774 patent/US20250228838A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250228838A1 (en) | Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders | |
| US9732059B2 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| US20250179044A1 (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| RU2840025C2 (ru) | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств | |
| CN119384295A (zh) | 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法 | |
| Kenji | Neuropharmacology of the Histaminergic system in the brain | |
| AU2010257456A1 (en) | 5 HT receptor mediated neurogensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |